



Aging and Hematological Neoplasms

Guest Editor:

Dr. Salvatrice Mancuso

Section of Hematology,
Department of Health Promotion
Sciences, Maternal and Infantile
Care, Internal Medicine and
Medical Specialties "G.
D'Alessandro", University of
Palermo, Palermo, Italy

Deadline for manuscript
submissions:

closed (31 March 2023)

Message from the Guest Editor

Most hematological neoplasms are predominantly diseases of older adults. Aging plays an important role in disease initiation and progression. Clonally restricted hematopoiesis is a common aging-associated biological state that predisposes to the development of a hematological malignancy. Potential drivers of progression from precursor states to overt neoplasia including secondary mutations in clonal cells, altered transcriptional program, marrow microenvironment inflammatory changes and immune exhaustion are also related to aging. Given the aging population and the concomitant increase in the number of older adults with cancer, the need to incorporate geriatric assessment into the care of elderly patients with hematological neoplasms is increasingly being recognized. Although significant progress has been made in recent years due to novel agents and strategies, these patients represent a group with the highest unmet medical need. The aim of this Special Issue is to address the complex relationship between aging and hematological neoplasms, including both biological and pathogenetic aspects as well as clinical and therapeutic challenges.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI